AbbVie Inc. is 80.5x more valuable than Xenon Pharmaceuticals Inc. by market capitalization ($399.47 B vs $4.96 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XENE | ABBV |
|---|---|---|
| Market cap | $4.96 B | $399.47 B |
| US-listed rank | #1390 | #28 |
| Revenue (latest FY) | $311.00K | $61.16B |
| Net income (latest FY) | -$345.91M | $4.23B |
| Net margin | -111225.1% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 763 | 1,008 |
AbbVie Inc. is 80.5x more valuable than Xenon Pharmaceuticals Inc. by market capitalization ($399.47 B vs $4.96 B).
In their latest fiscal years, Xenon Pharmaceuticals Inc. reported $311.00K in revenue while AbbVie Inc. reported $61.16B.
Full pages: Xenon Pharmaceuticals Inc. and AbbVie Inc., or browse the full rankings.